Why haven’t CAR-T therapies cracked into solid tumors yet? Poseida Therapeutics is trying to fill in at least one piece of the puzzle with a new analysis presented at the American Association for Cancer Research annual meeting showing that patients may need a higher dose of lymphodepletion than those with blood cancers.
Kite Gilead’s Kite shortens Yescarta manufacturing time with FDA nod
Kite Receives U.S. FDA Approval of Manufacturing Process Change
U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy
Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023
Analyses of Kite’s Yescarta® CAR T-Cell Therapy Support Curative Potential
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (Nasdaq: GILD), today announced results from the Phase 2 ALYCANTE study, led and sponsored by the French collaborative group LYSA/LYSARC, for use of its chimeric antigen receptor (CAR) T-cell therapy Yescarta® (axicabtagene ciloleucel) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after one prior line of therapy who were deemed ineligible for high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT). The full findings from the study were published in Nature Medicine.
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite Pharma, Inc., a Gilead Company (Nasdaq: GILD), today announced that the Marketing Authorization in Japan for Yescarta® (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T-cell therapy, has been transferred from Daiichi Sankyo Co., Ltd. to Gilead Sciences K.K., the Japan subsidiary of Gilead Sciences, Inc.
Kite – part of Gilead – has announced results from two real-world studies upholding the use of Yescarta among patients with relapsed/refractory (R/R) follicular lymphoma (FL) and Tecartus in R/R mantle cell lymphoma (MCL). The data has been duly presented at the European Hematology Association (EHA) 2023 annual congress in Germany.
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announces detailed results from the overall survival (OS) analysis of the landmark Phase 3 ZUMA-7 study of Yescarta® (axicabtagene ciloleucel [axi-cel]) CAR T-cell therapy compared with historical standard of care (SOC) as initial treatment in the curative setting for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL). Yescarta is the first treatment in nearly 30 years to demonstrate a significant improvement in survival in this patient population. The late-breaking data are being presented orally at the 2023 American Society of Clinical Oncology Annual Meeting (Abstract #LBA107) and published simultaneously in the New England Journal of Medicine.